Objectives: Attendees will learn the effectiveness of Combined use of Biostimulators and Energy based devices in the treatment of body laxity

Objectives: Abdominal laxity is a very common situation after rapid weight loss, postpartum, and the aging process. Knowing that we have tools to treat it and also how to treat it makes a difference. This presentation will share where to address the product, the number of vials, the maintenance, and when to avoid the treatment.

Objectives: * Provide an overview and update on advances in energy based devices for body contouring, skin tightening and cellulite
* Compare and contrast the mechanism of action behind the different technologies and their relative strengths and weaknesses
* Discuss and highlight the key role of aesthetic doctors and our knowledge of energy based / non-surgical body contouring in the weight loss revolution of semiglutide injectable drugs, and how these modalities can be utilized to treat the negative effects of “Ozempic body”

Objectives: Recently, the use of fillers with biostimulatory activities, such as CaHA, aiming at the increase of neocollagenesis, neoangiogenesis and increased elastin, has been proposed as an off-label treatment of skin laxity of the body.
Recently, we published a definition and classification for post-liposuction skin irregularities (PLSI). Previously unreported data related to treatment of PLSI with CaHA, leading to good-to-excellent results, will be presented.

Objectives: To evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat compared to placebo by using Abdominal Fat Rating Scale (AFRS) and MRI to assess the efficacy.

Introduction: CBL-514 is a lipolysis injection that can induce adipocyte apoptosis to reduce subcutaneous fat. The latest Phase 2b study showed that compared with the placebo group, the LS mean difference of the subcutaneous fat volume change eight weeks after CBL-514 treatments were -28.1 % (p< 0.001) and -276.8mL (p< 0.0001). The efficacy of CBL-514 for fat reduction is comparable to or exceeds that of liposuction, with a favorable safety profile.

Materials / method: A total of 107 participants with moderate to severe abdominal subcutaneous fat accumulation as assessed by the investigator via live evaluation using the CR-AFRS were enrolled and randomized in a 1:1 ratio to receive up to 4 treatments of allocated CBL-514 or placebo administered subcutaneously to the abdomen, once every 3 weeks, along with 3 follow-up visits at 4, 8, and 12 weeks post the last treatment

Results: All efficacy endpoints achieved. The results demonstrated that 81.8% of CBL-514-treated participants compared with placebo (16.7% and 18.5%)achieved at least 1-grade improvement. 58.8% of the participants only required one CBL-514 treatment to achieve at least 1-grade CR-AFRS improvement. Compared to the placebo group, CBL-514 reduced an average of over 31 % of abdominal subcutaneous fat thickness in PP population. Overall, the safety and tolerability profiles of CBL-514 were favorable and consistent with previous CBL-514 clinical studies.

Conclusion: CBL-514, the first-in-class new injectable drug for large-area fat reduction, appears to provide significant benefits for subcutaneous fat accumulation, suggesting it may be a promising, novel, better non-surgical fat reduction option warranting further Phase 3 investigation in a larger population.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Caliway Biopharmaceuticals

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Caliway Biopharmaceuticals/ Honorarium for Consulting

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Caliway Biopharmaceuticals